The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content (VLNC) cigarettes compared to 21 mg nicotine patch only and very low nicotine content cigarette only on abstinence, time to relapse and toxicant levels. The study will determine if adding nicotine replacement medication to the very low content cigarettes (VLNC) will augment treatment compared to nicotine patch only or to very low nicotine content cigarettes only.
The purpose of this study is to evaluate the effect of a combination of the 21 mg nicotine patch and very low nicotine content cigarette (VLNC) compared to the VLNC cigarette alone or 21 mg nicotine patch alone on abstinence, time to relapse and toxicant levels. The following primary hypothesis will be tested: Abstinence rates will be highest and the time to relapse will be the longest in the VLNC cigarettes plus nicotine patch condition compared to nicotine patch or VLNC cigarettes alone. Other hypotheses include: 1. Greater positive subjective responses to cigarettes will be observed with VLNC cigarettes plus patch vs. VLNC cigarette; 2. Less drop-outs will be observed in the VLNC plus patch vs the other two conditions; and 3. Less compensatory smoking will be observed in the VLNC plus patch condition compared to VLNC cigarette alone condition. Cigarette smokers will be randomized to: 1. VLNC cigarettes (which provide sensory behavioral aspects of smoking but with limited nicotine) plus nicotine patch for 6 weeks; 2. Nicotine patch for 6 weeks; or 3. VLNC cigarettes alone. Outcome measures will include cessation assessed at the end of treatment as the primary endpoint and at 36 weeks post-treatment, time to lapse and relapse to usual brand cigarettes, and biomarkers of toxicant exposure. Predictors of abstinence and treatment response for each of the treatment conditions will be explored.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Enrollment
235
21 mg
Cigarette where the tobacco contains \<0.1 mg of nicotine yield.
21 mg nicotine patch plus use of cigarette with tobacco containing \<0.1 mg nicotine yield.
University of Minnesota
Duluth, Minnesota, United States
University of MN's Tobacco Use Research Center
Minneapolis, Minnesota, United States
End of Treatment Abstinence Rate
Cotinine and carbon monoxide (CO) verified point prevalence abstinence
Time frame: 12 week
End of Follow-up Abstinence Rates
CO- and cotinine-verified point prevalence abstinence
Time frame: 36 weeks
Exposure to Tobacco Toxicants
Time frame: 6 weeks
Time to Lapse or Relapse to Tobacco Use
Time frame: 26 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.